On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVIDﾙ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval.

This included all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that had transitioned from lower-middle to upper-middle-income status in the last five years, accounting for approximately 53% of the worldﾒs population.